{"DataElement":{"publicId":"6825109","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Amyloidosis Peripheral Nervous System Status Type","preferredDefinition":"A description of the best peripheral nervous system response to therapy for amyloidosis.","longName":"2946463v1.0:6825061v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6825061","version":"1","preferredName":"Amyloidosis Peripheral Nervous System Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"6825061v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not assessed","valueDescription":"Not Done","ValueMeaning":{"publicId":"4163021","version":"1","preferredName":"Not Done","longName":"4163021","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B5E544-9A39-F7D4-E040-BB89AD4312F7","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9004D31D-BD8E-1936-E053-F662850A1F2F","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-08-13","modifiedBy":"ONEDATA","dateModified":"2019-08-13","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E711490-0DA7-04B9-E053-F662850AECB9","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Peripheral nervous system progression","valueDescription":"Peripheral nervous system progression","ValueMeaning":{"publicId":"6825062","version":"1","preferredName":"Peripheral nervous system progression","longName":"6825062","preferredDefinition":"Progressive neuropathy by electromyography or nerve conduction velocity","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E711490-0DC5-04B9-E053-F662850AECB9","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E711490-0DDE-04B9-E053-F662850AECB9","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"No response / stable disease","valueDescription":"No response / stable disease","ValueMeaning":{"publicId":"6825063","version":"1","preferredName":"No response / stable disease","longName":"6825063","preferredDefinition":"Does not meet the criteria for peripheral nervous system response or peripheral nervous system progression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E711490-0DE8-04B9-E053-F662850AECB9","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E711490-0E00-04B9-E053-F662850AECB9","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Peripheral nervous system response","valueDescription":"Peripheral nervous system response","ValueMeaning":{"publicId":"6825064","version":"1","preferredName":"Peripheral nervous system response","longName":"6825064","preferredDefinition":"Improvement in electromyogram nerve conduction velocity (rare)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E711490-0E0A-04B9-E053-F662850AECB9","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"KUMMEROA","dateModified":"2019-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E711490-0E23-04B9-E053-F662850AECB9","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6825060","version":"1","preferredName":"Amyloidosis Peripheral Nervous System Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.:That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.:A condition or state at a particular time.:Something distinguishable as an identifiable class based on common qualities.","longName":"C2868:C12465:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Peripheral Nervous System","conceptCode":"C12465","definition":"That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E711490-0D80-04B9-E053-F662850AECB9","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E711490-0D91-04B9-E053-F662850AECB9","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the best peripheral n","type":"Preferred Question Text","description":"What is the best peripheral nervous system response to therapy for amyloidosis?","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best peripheral nervous system response_1","type":"Alternate Question Text","description":"Specify the recipient's best peripheral nervous system response","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best peripheral nervous system response_2","type":"Application Standard Question Text","description":"Specify the recipient's best peripheral nervous system response","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best peripheral nervous system response","type":"Alternate Question Text","description":"Specify the recipient's best peripheral nervous system response","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E712AC9-F136-04B5-E053-F662850A4B6F","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-24","modifiedBy":"TYRRELLM","dateModified":"2023-07-20","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.  QT not displaying correctly in FDM - AQT added 09/25/2019 KMM","administrativeNotes":"7/20/23 removed special character from AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"}}